Therapeutic agents and treatment methods for urologic cancers, particularly urologic cancers with reduced lysine (K)-specific demethylase 6A (KDM6A) function, the agents and methods being characterized by suppressing both IL-6 activity and CCR2/CCL2 activity, are provided.

Therapeutic agents and treatment methods for urologic cancers, particularly urologic cancers with reduced lysine (K)-specific demethylase 6A (KDM6A) function, the agents and methods being characterized by suppressing both IL-6 activity and CCR2/CCL2 activity, are provided.

The present invention relates generally to suppositories that release nitric oxide, and methods of using the same.

The present invention relates generally to suppositories that release nitric oxide, and methods of using the same.

This invention relates to compositions and methods for promoting and/or accelerating bone regeneration, repair, and/or healing and, in particular, to compositions and methods of promoting bone regeneration, growth, repair, and/or healing using graft or scaffold materials. In exemplary embodiments, the disclosed compositions may be used to promote and/or accelerate bone regeneration by delivering a composition to a bone site, the composition comprising (a) a citrate component, (b) a phosphate component, and, optionally, (c) a particulate inorganic material. The citrate component and/or phosphate component is advantageously released from the composition at the bone site. The released citrate component may function to increase alkaline phosphatase activity and/or expression at the bone site, and the increased alkaline phosphatase activity and/or expression may release the phosphate component. The composition may be delivered in various forms, e.g., as a biodegradable scaffold.

This invention relates to compositions and methods for promoting and/or accelerating bone regeneration, repair, and/or healing and, in particular, to compositions and methods of promoting bone regeneration, growth, repair, and/or healing using graft or scaffold materials. In exemplary embodiments, the disclosed compositions may be used to promote and/or accelerate bone regeneration by delivering a composition to a bone site, the composition comprising (a) a citrate component, (b) a phosphate component, and, optionally, (c) a particulate inorganic material. The citrate component and/or phosphate component is advantageously released from the composition at the bone site. The released citrate component may function to increase alkaline phosphatase activity and/or expression at the bone site, and the increased alkaline phosphatase activity and/or expression may release the phosphate component. The composition may be delivered in various forms, e.g., as a biodegradable scaffold.

Pharmaceutical composition comprising a pharmaceutically effective amount of bioavailable silicon in a daily dose of at least 3 mg elemental silicon, and a pharmaceutically effective amount of a magnesium compound in a daily dose of 50-500 mg elemental magnesium. The composition is used for prevention, inhibition and/or treatment of muscle cramps, such as skeletal muscle cramps.

Pharmaceutical composition comprising a pharmaceutically effective amount of bioavailable silicon in a daily dose of at least 3 mg elemental silicon, and a pharmaceutically effective amount of a magnesium compound in a daily dose of 50-500 mg elemental magnesium. The composition is used for prevention, inhibition and/or treatment of muscle cramps, such as skeletal muscle cramps.

Topical compositions for protecting the skin of a mammal from the transfer of heat from a surface are described herein. The compositions include a base formulation and additives. In some instances, the additives include thermally-insulating nanoparticles and/or microparticles, and one or more of a dimethicone, a cyclomethicone, and an amodimethicone. In some instances, the additives include a silicone acrylate emulsion, the silicone acrylate emulsion comprising a blend of about 30% of acrylates/polytrimethylsiloxy-methacrylate copolymer anionic emulsion and laureth-1 phosphate and, optionally, thermally-insulating nanoparticles and/or microparticles. In some instances, the additives include a 60% non-ionic emulsion of a polydimethylsiloxane/vinyl copolymer having a viscosity of greater than 120×10.sup.6 mm.sup.2/s at 0.01 Hz, and having C12-13 Pareth-23 and C12-13 Pareth-3 and, optionally, thermally-insulating nanoparticles and/or microparticles.

Topical compositions for protecting the skin of a mammal from the transfer of heat from a surface are described herein. The compositions include a base formulation and additives. In some instances, the additives include thermally-insulating nanoparticles and/or microparticles, and one or more of a dimethicone, a cyclomethicone, and an amodimethicone. In some instances, the additives include a silicone acrylate emulsion, the silicone acrylate emulsion comprising a blend of about 30% of acrylates/polytrimethylsiloxy-methacrylate copolymer anionic emulsion and laureth-1 phosphate and, optionally, thermally-insulating nanoparticles and/or microparticles. In some instances, the additives include a 60% non-ionic emulsion of a polydimethylsiloxane/vinyl copolymer having a viscosity of greater than 120×10.sup.6 mm.sup.2/s at 0.01 Hz, and having C12-13 Pareth-23 and C12-13 Pareth-3 and, optionally, thermally-insulating nanoparticles and/or microparticles.